Created with Highcharts 4.1.4Chart context menuChart context menuChart context menuChart context menuChart context menuChart context menu
Dispensing Pharmacy Business Net sales
FY2020FY2021FY2022FY2023FY2024FY2025
0100,000200,000300,000400,000
( million yen )
54,814
58,200
62,912
66,375
72,309
76,643
111,763
118,236
128,749
136,180
147,605
156,569
170,695
181,125
197,389
208,076
225,570
240,266
231,001
244,072
265,624
280,164
302,805
1Q
2Q
3Q
FY
Created with Highcharts 4.1.4Chart context menuChart context menuChart context menuChart context menuChart context menuChart context menu
Dispensing Pharmacy Business Operating profit
FY2020FY2021FY2022FY2023FY2024FY2025
05,00010,00015,00020,000
( million yen )
1,843
464
1,888
2,062
2,907
1,729
4,408
3,624
5,041
5,993
6,016
4,509
6,581
6,991
9,108
10,601
10,628
9,103
9,785
10,585
13,009
14,666
15,189
1Q
2Q
3Q
FY

( million yen )
FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Dispensing Pharmacy Business Net sales 231,001 244,072 265,624 280,164 302,805 -
Dispensing Pharmacy Business Operating profit 9,785 10,585 13,009 14,666 15,189 -
Created with Highcharts 4.1.4Chart context menuChart context menuChart context menuChart context menuChart context menuChart context menu
Pharmaceutical Manufacturing and Sales Business Net sales
FY2020FY2021FY2022FY2023FY2024FY2025
010,00020,00030,00040,00050,000
( million yen )
10,881
12,073
12,158
10,027
10,530
9,945
21,040
22,812
23,669
19,194
20,487
19,570
32,564
35,235
35,274
29,316
31,163
30,903
43,072
45,699
44,836
38,575
40,446
1Q
2Q
3Q
FY
Created with Highcharts 4.1.4Chart context menuChart context menuChart context menuChart context menuChart context menuChart context menu
Pharmaceutical Manufacturing and Sales Business Operating profit
FY2020FY2021FY2022FY2023FY2024FY2025
-2,000-1,00001,0002,0003,000
( million yen )
798
833
451
270
126
-461
1,155
1,163
195
-396
167
-652
1,534
2,205
1,294
-456
555
-300
1,301
2,350
-53
-1,392
250
1Q
2Q
3Q
FY

( million yen )
FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Pharmaceutical Manufacturing and Sales Business Net sales 43,072 45,699 44,836 38,575 40,446 -
Pharmaceutical Manufacturing and Sales Business Operating profit 1,301 2,350 -53 -1,392 250 -
Created with Highcharts 4.1.4Chart context menuChart context menuChart context menuChart context menuChart context menuChart context menu
Medical Professional Staffing and Placement Business Net sales
FY2020FY2021FY2022FY2023FY2024FY2025
02,5005,0007,50010,00012,50015,000
( million yen )
3,597
2,943
1,901
2,066
2,580
3,296
6,775
5,025
3,648
3,959
4,945
6,021
9,737
6,644
5,207
5,909
7,370
8,678
12,721
8,393
6,991
8,063
9,984
1Q
2Q
3Q
FY
Created with Highcharts 4.1.4Chart context menuChart context menuChart context menuChart context menuChart context menuChart context menu
Medical Professional Staffing and Placement Business Operating profit
FY2020FY2021FY2022FY2023FY2024FY2025
05001,0001,5002,000
( million yen )
651
509
278
355
484
663
1,082
696
440
500
698
766
1,442
653
423
602
795
805
1,851
712
576
758
937
1Q
2Q
3Q
FY

( million yen )
FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Medical Professional Staffing and Placement Business Net sales 12,721 8,393 6,991 8,063 9,984 -
Medical Professional Staffing and Placement Business Operating profit 1,851 712 576 758 937 -

Caution

  • These data are prepared based on the financial results reports.

  • The frequency of updates may change in accordance with changes to the format of the financial results reports.

  • Please see the financial results reports and other materials for detailed information regarding the settlement of accounts.

  • The contents of these data will not immediately reflect corrections to the financial results reports when announced.

  • While we pay due caution to the conversion of data for the posting, please note that there is a possibility that errors may occur in the information due to uncontrollable circumstances, such as the unauthorized alteration of contents by a third party or mechanical defects resulting from equipment malfunction.

  • Service provided by Nomura Investor Relations Co., Ltd.

  • We conducted a 2-for-1 stock split effective on April 1, 2020 and we make retroactive adjustments to related indicators.

Powered by